105results about "Mass spectrometric analysis" patented technology

The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.

By adapting isotopic fingerprinting to the human body, experimental data revealed a specific chemical fingerprint of cancer, such as prostate cancer, "fossilized" in samples such as a patient's hair or nails. To interpret the isotopic chemical data of the samples, a predictive model was developed using machine learning algorithms and several dimensions to enable population differentiation. In several aspects, this provides a non-invasive method for cancer diagnosis, detection, or assessment developed by identifying the chemical fingerprint of cancer. TIFF2026509162000028.tif53159

Provided are methods for determining the amount of estrone in a sample using mass spectrometry. The methods generally involve ionizing estrone in a sample and detecting and quantifying the amount of the ion to determine the amount of estrone in the sample.

This invention provides compositions and treatment methods for reducing hyperphenylalaninemia. [Solution] A genetically modified bacterium is provided, comprising: a) one or more genes encoding phenylalanine ammonia lyase (PAL), which are operably linked to a promoter that is not naturally associated with the PAL gene and can be directly or indirectly induced; b) one or more genes encoding a phenylalanine transporter, which are not naturally associated with the phenylalanine transporter gene and can be operably linked to a promoter that is directly or indirectly induceable; and c) one or more genes encoding mutant fumarate and nitrate reductase (FNR), which are not naturally associated with the FNR gene and can be operably linked to a promoter that is directly or indirectly induceable.

An IROA Matrix of metabolite compounds is disclosed. Each of whose compounds has a molecular weight of 2000 AMU or less, and is present as first and second isotopomers that are equally present at two predetermined isotopomeric balances, and contain 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. A reagent pair for transforming a natural abundance mass spectral analysis metabolite sample into an IROA sample is also disclosed and comprises two reactively identical reagents that constitute first and second isotopomers containing 2 to 10% of a first isotope, and 90 to 98% of a second isotope, respectively. Each of the reagent pair contains the same reactive group that reacts with and bonds to a functional group of one or more compounds present in a composition of biologically-produced metabolite compounds. Methods of making and using the above and related materials are also disclosed.

Provided are: a method which is for analyzing a neurogranin-related peptide and can suppress deviations in analysis results; and a method for preparing a biological sample containing the neurogranin-related peptide used for same. A method for preparing a sample solution containing a neurogranin-related peptide involves mixing a biological sample containing the neurogranin-related peptide with an organic solvent having a relative polarity of 0.200 to 0.700 to prepare a sample solution containing the organic solvent having a final concentration of at least 5.0 (v / v)%.

The present disclosure provides methods and materials for screening a compound or monitoring a subject's response to a compound or dosing regimen for treating a PGRN-associated disorder. Methods and materials for identifying and treating a subject having a PGRN-associated disorder are also provided.

The present invention relates to a method for determining the sex of a fetus in an ungulate.

The invention relates to a panel of biomarkers, comprising or consisting of: benzene, benzothiazole, decane, isothiocyanato-cyclohexane, methylstyrene, phenol, styrene, toluene, 1-hexanol, 2-butoxyethanol, and p-xylene. In particular to the use of this panel in i) diagnosing eosinophilia in a subject, ii) treating an asthmatic subject with eosinophilia and / or who is suffering severe exacerbations, or iii) monitoring treatment efficacy in a subject with eosinophilia and / or who is suffering severe exacerbations.

The present invention describes a comprehensive system and method for the simultaneous early detection of multiple cancers in a single analysis. The system involves a liquid chromatography-mass spectrometry (LC-MS) instrument coupled with a processor and AI / ML algorithms. The LC-MS instrument analyzes metabolite ions from dried extracts of biological fluid samples and aligns and normalizes the data while minimizing errors. Quality control processes, including neural network models and critical ion monitoring, ensure accurate detection. The system employs an AI / ML process to create two models: a Cancer Detection AI (CDAI) model for identifying cancer samples and a Tissue of Origin Identification (TOOAI) model for distinguishing specific cancer types. These models are applied to test samples and provide a score based on tissue of origin probability. The present invention aims to revolutionize early cancer detection through advanced analytical and machine learning techniques.

The invention discloses a partial acylated non-natural sugar for metabolic labeling and application, the partial acylated non-natural sugar is a mannose type of a pyranose structure, and 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups. According to the method, the advantages of existing non-natural sugar are taken into consideration, it is guaranteed that the non-natural sugar can be efficiently utilized by cells, S side reaction of the non-natural sugar and cysteine in protein in the metabolism process is effectively avoided, and meanwhile efficient metabolism marking is achieved. In a cell test, the use concentration of the 1, 6-diacylated non-natural sugar is one order of magnitude lower than that of the non-natural sugar without the protecting group.

Methods are provided for detecting the amount of one or more CAH panel analytes (i.e., pregnenolone, 17-OH pregnenolone, progesterone, 17-OH progesterone, dehydroepiandrosterone (DHEA), androstenedione, testosterone, deoxycorticosterone, 11-deoxycortisol, and cortisol) in a sample by mass spectrometry. The methods generally involve ionizing one or more CAH panel analytes in a sample and quantifying the generated ions to determine the amount of one or more CAH panel analytes in the sample. In methods where amounts of multiple CAH panel analytes are detected, the amounts of multiple analytes are detected in the same sample injection.

A method of obtaining and processing a tear sample from an individual, including obtaining a sample of tears from an individual by use of a flexible tapered polymer structure having opening at a distal end thereof, the opening having a diameter of less than 1 millimeter and placing the distal end of the flexible tapered polymer structure into contact with the tears adjacent the eye and applying negative pressure to the flexible tapered polymer structure. The method further includes buffering the sample of tears by addition of a buffering solution, analyzing the sample of tears to identify cannabinoids within the sample of tears; and presenting results of analysis of the sample of tears.

A method for characterizing or quantifying one or more proteins in visible and / or sub-visible particles formed in a sample by detecting the at least one visible or sub-visible particle in the sample, isolating and capturing the at least one visible or sub-visible particle to identify a presence of a protein, and using a mass spectrometer to characterize the protein.

Immunohistochemistry (INC) and in situ hybridization (ISH) methods are used for the targeted detection and localization of biomolecules (e.g., proteins and miRNAs) in tissues or cells, for research applications and clinical applications such as those of pathologists (e.g., biomarker analysis of resected tumors or tumor biopsies). These methods include mass spectrometry imaging (MSI) as a mode for detecting and localizing biomolecules in tissues or cells. The methods employ optically cleavable mass-tagged reagents linked to probes such as antibodies and nucleic acids and used to enable multiplexed immunohistochemistry and in situ hybridization, with MSI as the detection / readout mode. The methods also include multi-omics MSI procedures in which MSI of optically cleavable mass-tagged probes is combined with other MSI modes, such as direct label-free MSI of endogenous biomolecules from biological samples (e.g., tissues).

The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.

In a general aspect, methods and devices for using mass spectrometry to identify endometriosis are provided.SOLUTION: In some embodiments, a fixed or discrete volume of solvent is applied to the tissue site containing the potential endometriotic tissue. The applied solvent is collected to obtain a liquid sample. The liquid sample is subjected to mass spectrometry. The fluid sample is retrieved from a tissue site in vivo during a medical procedure. The mass spectrometry data is analyzed to identify whether the tissue site contains endometriosis.SELECTED DRAWING: Figure 2

Described herein are reagents and methods for improving signal in imaging mass cytometry. Aspects include mass tags with a large number of labeling atoms, chemical modifications to mass tags and additional reagents to reduce background and / or maintain target binding of mass tagged specific binding partners (SBPs), and schemes for associating a plurality of mass tags with a single SBP. As such, embodiments include any combination of one or more reagents and their use. The reagents, kits and methods herein may be used for mass cytometry, including imaging mass cytometry. In some aspects, reagents, kits or methods may be used for delivery of a large number of radioisotopes to a target analyte, for example for therapeutic use or radiometric detection. In certain aspects, only non-radioactive isotopes may be used for mass cytometry.

The invention provides a method for detecting one or more analytes, the method comprising: providing a substrate comprising a semiconductor with a porous surface, wherein the porous surface is coated with a fluorocarbon polymeric coating; contacting the porous surface with a fluid or object so that the one or more analytes are retained on the substrate when present in the fluid or on the object; and analysing the substrate by mass spectrometry to detect the one or more analytes if present on the substrate.

The application discloses a non-natural sugar and a synthesis method and application thereof. At room temperature, hydroxyl groups of an amino sugar are fully trimethylsilyl-protected, amino groups on the sugar are selectively exposed, and after coupling and conversion of the amino groups at room temperature, a non-natural sugar with orthogonal groups and full trimethylsilyl protection is obtained. The non-natural sugar with orthogonal groups and full trimethylsilyl protection is removed from trimethylsilyl protection groups, and a non-natural sugar without protection groups is obtained. The application takes into account the advantages of existing non-natural sugars, ensures that the non-natural sugars can be efficiently utilized by cells, effectively avoids S side reactions with cysteine in proteins in the metabolic process of the non-natural sugars, and simultaneously realizes efficient metabolic labeling. In a cell test, the use concentration of 1,6-bisacylated non-natural sugar is one order of magnitude lower than that of non-natural sugar without protection groups.

A multiplex method for co-detecting a plurality of different types of biomarkers in a tissue sample on a single slide comprises: (a) providing a tissue sample on a single slide; (b) performing antigen

A method for determining a combined amount of β-tocopherol and γ-tocopherol in a sample by tandem mass spectrometry includes subjecting the sample to ionization under conditions suitable to produce one or more ions from the β-tocopherol and γ-tocopherol detectable by mass spectrometry; and determining the amount of one or more of said ions by tandem mass spectrometry, wherein tandem mass spectrometry comprises fragmenting β-tocopherol and γ-tocopherol ions having a mass to charge ratio of about 416.35±0.80 into one or more fragment ions comprising a fragment ion having a mass to charge ratio of about 151.00±0.80, wherein the amount of the one or more ions determined is related to the combined amount of β-tocopherol and γ-tocopherol in the sample.

Provided herein are methods for detecting the risk or presence of a metabolic dysfunction or age-related disease in a subject. Also provided herein are methods for identifying a subject at risk or presence in need of treatment of metabolic dysfunction or age-related disease.

To provide a method for identifying NAFLD with excellent identification performance and a biomarker used in the method. An identification method for nonalcoholic fatty liver disease includes: an acquisition step of acquiring a sample derived from a body fluid of a subject; a detection step of detecting eight kinds of compounds consisting of alanine, isoleucine, glycine, serine, glutamic acid, asparagine, tyrosine, and uric acid in the sample; and a use step of using all detection amounts of the eight kinds of compounds obtained in the detection step.

The invention relates to the quantitative measurement of steroidal compounds by mass spectrometry. In a particular aspect, the invention relates to methods for quantitative measurement of steroidal compounds from multiple samples by mass spectrometry.

The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and / or the presence or amount of enzymes involved in cardiolipin remodeling.

A method for quantifying Hex4, lyso-GM1, Fuc-GlcNAc-Asn, or lyso-sulfatide included in cerebrospinal fluid, the method including adding an internal standard substance to a solution including the cerebrospinal fluid, submitting the solution including the cerebrospinal fluid, to which the internal standard substance has been added, to liquid chromatography to obtain an eluate, and subjecting the eluate to mass analysis.

A system and method is provided for validating the manufacturing process for the production of complex biological compositions, and particularly for providing process validation information for evaluation by a federal regulatory agency. The system and method continuously and chronologically assess the concentration of proteoforms within the biological composition as it is being produced in a fermentor. Samples from the fermentor are analyzed in a pre-selected array of analysis columns, with data generated by the columns being accumulated and evaluated, and particularly compared with data from previous stages in the production process. A continuous process validation system includes top-down and bottom-up analysis sectors, each including a plurality of different analysis columns that can be selected by the controller for a particular biological composition and a particular production process.

The present disclosure relates to a method for quantifying mRNA capping efficiency. The method uses a detectable label to quantify the amount of unlabeled mRNA in a sample. The method is applicable to RNA molecules of any sequence, and can be used to obtain information on the physical properties of an RNA sample. The present disclosure also relates to a kit that can be used to quantify mRNA capping efficiency.

Provided are methods for detecting or determining the amount of guanidinoacetate (GAA), creatine, and creatinine by mass spectrometry.